MTP-1307, 7,8-dihydro-2-(4-methylpiperazinyl)-4-(1-pyrrolidinyl)-6H- thiopyrano[3,2-d]
pyrimidine dimaleate, is a novel oral
hypoglycemic agent, structurally different from any existing
hypoglycemic drugs. In fasted rats, the
hypoglycemic effect of
MTP-1307 was accompanied by elevation of the plasma
insulin. In
glucose tolerance tests,
MTP-1307 suppressed the
hyperglycemia after
glucose loading and significantly enhanced the
glucose-induced insulin secretion. In isolated hepatocytes from fasted rats,
MTP-1307 inhibited gluconeogenesis from
lactate and
alanine. Furthermore,
MTP-1307 increased the
lactate/
pyruvate ratio but did not increase the
lactate level.
MTP-1307 did not influence glycogenolysis in isolated hepatocytes from fed rats. In genetically diabetic ob/ob mice,
MTP-1307 decreased the
blood glucose level and improved
glucose tolerance, but did not affect the level of plasma
insulin.
MTP-1307 increased 14CO2 production from
glucose in isolated epididymal fat pads of ob/ob mice. Thus, these findings suggest that
MTP-1307 produces
hypoglycemic activities not only in normal animals but also in genetically diabetic animals, and that the
hypoglycemic mechanism of
MTP-1307 involves the promotion of
glucose utilization in adipose tissue and, partially, the inhibition of gluconeogenesis in the liver and the stimulation of
insulin release from the pancreas.